Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company, reported a solid start to 2025, with notable financial improvements and growing momentum in its core business segment.
The company operates through two primary businesses: the Minimal Residual Disease (MRD) business and the Immune Medicine (IM) business.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com